JD Health International Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Enlin Jin

Chief executive officer

CN¥8.4m

Total compensation

CEO salary percentage	15.0%
CEO tenure	3.2yrs
CEO ownership	0.01%
Management average tenure	no data
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Enlin Jin's remuneration changed compared to JD Health International's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥8m	CN¥1m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥1b
Dec 31 2022	CN¥8m	CN¥1m	CN¥380m
Sep 30 2022	n/a	n/a	-CN¥7m
Jun 30 2022	n/a	n/a	-CN¥395m
Mar 31 2022	n/a	n/a	-CN¥734m
Dec 31 2021	CN¥3m	CN¥301k	-CN¥1b

Compensation vs Market: Enlin's total compensation ($USD1.16M) is about average for companies of similar size in the Hong Kong market ($USD907.21K).

Compensation vs Earnings: Enlin's compensation has been consistent with company performance over the past year.

CEO

Enlin Jin (43 yo)

3.2yrs

Tenure

CN¥8,385,000

Compensation

Mr. Enlin Jin is Chief Executive Officer & Executive Director of JD Health International Inc. from September 06, 2021. Mr. Jin has extensive experience in pharmaceuticals and TMT industry. He serves as the...

Board Members

Name	Position	Tenure	Compensation	Ownership
Enlin Jin	CEO & Executive Director	3.2yrs	CN¥8.39m	0.011% HK$ 9.6m
Ying Wu	Independent Non-Executive Director	2.6yrs	CN¥818.00k	0.00030% HK$ 267.5k
Qiangdong Liu	Chairman	4.2yrs	CN¥407.82m	0.56% HK$ 495.3m
Qingqing Yi	Non-Executive Director	4.3yrs	no data	no data
Xingyao Chen	Independent Non-Executive Director	4yrs	CN¥476.00k	0.00018% HK$ 160.5k
Ling Li	Independent Non-Executive Director	4yrs	CN¥476.00k	0.00018% HK$ 160.5k
Jiyu Zhang	Independent Non-Executive Director	3.7yrs	CN¥463.00k	0.00019% HK$ 169.4k

4.0yrs

Average Tenure

51yo

Average Age

Experienced Board: 6618's board of directors are considered experienced (4 years average tenure).

JD Health International Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Now 23% undervalued after recent price drop

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 18%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

Now 23% undervalued

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold HK$5.1m worth of stock

Independent Non-Executive Director recently sold HK$55k worth of stock

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold HK$195m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

Independent Non-Executive Director recently sold HK$61k worth of stock

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share (vs CN¥0.45 loss in FY 2019)

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021